Celltrion's 'Remsima SC' Approved for Sale in Canada
[Asia Economy Reporter Chunhee Lee] Celltrion announced on the 1st that its infliximab subcutaneous injection formulation autoimmune disease treatment 'RemsimaSC' received sales approval from Health Canada on the 28th of last month (local time).
This approval of RemsimaSC in Canada was granted for the indication of rheumatoid arthritis (RA). Celltrion plans to apply for approval for the indication of inflammatory bowel disease (IBD) in the future.
RemsimaSC is a bio-pharmaceutical developed by Celltrion by changing the formulation of Remsima from the existing intravenous injection to subcutaneous injection (SC). This allows patients to self-inject at their desired location without visiting a hospital, greatly improving treatment convenience.
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- Samsung Enterprise Labor Union: "We Respect Court’s Injunction Decision... General Strike to Proceed on the 21st as Planned"
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- Special Counsel on Insurrection Urges Swift Decision on 'Recusal Requests' by Yoon Seok-yeol and Others, Citing 'Clear Intent to Delay'
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
A Celltrion official said, "We expect this approval to serve as a foothold for entry into the North American market, including the United States," and "we also plan to proceed smoothly with additional approval applications such as for the IBD indication."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
